S&P 500   4,298.88 (+0.57%)
DOW   33,626.30 (+0.23%)
QQQ   358.98 (+1.11%)
AAPL   171.47 (+0.61%)
MSFT   314.60 (+0.58%)
META   305.10 (+2.47%)
GOOGL   132.82 (+1.75%)
AMZN   126.09 (+0.09%)
TSLA   245.68 (+2.15%)
NVDA   432.17 (+1.76%)
NIO   8.90 (+5.20%)
BABA   85.45 (-0.86%)
AMD   103.48 (+5.52%)
T   14.93 (+0.40%)
F   12.60 (+1.69%)
MU   65.62 (-3.80%)
CGC   0.82 (-7.91%)
GE   112.46 (+1.42%)
DIS   80.00 (+0.13%)
AMC   7.63 (+0.79%)
PFE   32.01 (-0.28%)
PYPL   58.13 (+1.38%)
NFLX   376.36 (-0.33%)
S&P 500   4,298.88 (+0.57%)
DOW   33,626.30 (+0.23%)
QQQ   358.98 (+1.11%)
AAPL   171.47 (+0.61%)
MSFT   314.60 (+0.58%)
META   305.10 (+2.47%)
GOOGL   132.82 (+1.75%)
AMZN   126.09 (+0.09%)
TSLA   245.68 (+2.15%)
NVDA   432.17 (+1.76%)
NIO   8.90 (+5.20%)
BABA   85.45 (-0.86%)
AMD   103.48 (+5.52%)
T   14.93 (+0.40%)
F   12.60 (+1.69%)
MU   65.62 (-3.80%)
CGC   0.82 (-7.91%)
GE   112.46 (+1.42%)
DIS   80.00 (+0.13%)
AMC   7.63 (+0.79%)
PFE   32.01 (-0.28%)
PYPL   58.13 (+1.38%)
NFLX   376.36 (-0.33%)
S&P 500   4,298.88 (+0.57%)
DOW   33,626.30 (+0.23%)
QQQ   358.98 (+1.11%)
AAPL   171.47 (+0.61%)
MSFT   314.60 (+0.58%)
META   305.10 (+2.47%)
GOOGL   132.82 (+1.75%)
AMZN   126.09 (+0.09%)
TSLA   245.68 (+2.15%)
NVDA   432.17 (+1.76%)
NIO   8.90 (+5.20%)
BABA   85.45 (-0.86%)
AMD   103.48 (+5.52%)
T   14.93 (+0.40%)
F   12.60 (+1.69%)
MU   65.62 (-3.80%)
CGC   0.82 (-7.91%)
GE   112.46 (+1.42%)
DIS   80.00 (+0.13%)
AMC   7.63 (+0.79%)
PFE   32.01 (-0.28%)
PYPL   58.13 (+1.38%)
NFLX   376.36 (-0.33%)
S&P 500   4,298.88 (+0.57%)
DOW   33,626.30 (+0.23%)
QQQ   358.98 (+1.11%)
AAPL   171.47 (+0.61%)
MSFT   314.60 (+0.58%)
META   305.10 (+2.47%)
GOOGL   132.82 (+1.75%)
AMZN   126.09 (+0.09%)
TSLA   245.68 (+2.15%)
NVDA   432.17 (+1.76%)
NIO   8.90 (+5.20%)
BABA   85.45 (-0.86%)
AMD   103.48 (+5.52%)
T   14.93 (+0.40%)
F   12.60 (+1.69%)
MU   65.62 (-3.80%)
CGC   0.82 (-7.91%)
GE   112.46 (+1.42%)
DIS   80.00 (+0.13%)
AMC   7.63 (+0.79%)
PFE   32.01 (-0.28%)
PYPL   58.13 (+1.38%)
NFLX   376.36 (-0.33%)
NYSE:MED

Medifast (MED) Stock Forecast, Price & News

$77.35
+0.73 (+0.95%)
(As of 12:55 PM ET)
Compare
Today's Range
$76.46
$77.46
50-Day Range
$76.56
$106.93
52-Week Range
$76.46
$131.42
Volume
41,541 shs
Average Volume
198,193 shs
Market Capitalization
$842.34 million
P/E Ratio
6.38
Dividend Yield
8.53%
Price Target
$80.00

Medifast MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
3.8% Upside
$80.00 Price Target
Short Interest
Bearish
15.54% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-4.08
Upright™ Environmental Score
News Sentiment
0.54mentions of Medifast in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.40 M Sold Last Quarter
Proj. Earnings Growth
-13.33%
From $8.78 to $7.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Consumer Staples Sector

125th out of 135 stocks

Miscellaneous Food Preparations & Kindred Products Industry

4th out of 4 stocks


MED stock logo

About Medifast (NYSE:MED) Stock

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.

MED Price History

MED Stock News Headlines

Are These Consumer Staples Too Cheap for Investors To Ignore? (MED)
The consumer staples sector is beaten down and offering a significant value and high yield for long-term-minded investors
Medifast (NYSE:MED) Hits New 12-Month Low at $77.46
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
30 Most Overweight and Obese Cities in the U.S. In 2023
What Is Medifast, Inc.'s (NYSE:MED) Share Price Doing?
OPTAVIA ACTIVE™ Now Available
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Q2 2023 Medifast Inc Earnings Call
See More Headlines
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

MED Company Calendar

Ex-Dividend for 8/8 Dividend
6/26/2023
Last Earnings
8/07/2023
Dividend Payable
8/08/2023
Ex-Dividend for 11/7 Dividend
9/18/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Dividend Payable
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
874
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$80.00
Forecasted Upside/Downside
+4.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$143.57 million
Pretax Margin
12.58%

Debt

Sales & Book Value

Annual Sales
$1.60 billion
Cash Flow
$15.72 per share
Book Value
$14.19 per share

Miscellaneous

Free Float
10,665,000
Market Cap
$833.74 million
Optionable
Optionable
Beta
1.24
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Daniel R. ChardMr. Daniel R. Chard (Age 58)
    Exec. Chairman & CEO
    Comp: $1.94M
  • Mr. James P. Maloney CPA (Age 55)
    Chief Financial Officer
    Comp: $823.91k
  • Mr. Anthony E. Tyree (Age 58)
    Chief Bus. Operations Officer
    Comp: $655.86k
  • Mr. Jason L. Groves Esq. (Age 52)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $669.51k
  • Mr. Nicholas M. Johnson (Age 43)
    Chief Field Operations Officer
    Comp: $696.4k
  • Mr. Jonathan Barrett MacKenzie (Age 51)
    VP of Fin. & Chief Accounting Officer
  • Mr. Steven Zenker
    VP of Investor Relations
  • Ms. Claudia C. Greninger (Age 50)
    Chief HR Officer













MED Stock - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price forecast for 2023?

1 brokerages have issued 1 year price objectives for Medifast's shares. Their MED share price forecasts range from $80.00 to $80.00. On average, they expect the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2023?

Medifast's stock was trading at $115.35 at the beginning of 2023. Since then, MED shares have decreased by 33.6% and is now trading at $76.56.
View the best growth stocks for 2023 here
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MED earnings forecast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) released its quarterly earnings data on Monday, August, 7th. The specialty retailer reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $1.33. The specialty retailer had revenue of $296.20 million for the quarter, compared to analysts' expectations of $270.20 million. Medifast had a net margin of 9.68% and a trailing twelve-month return on equity of 89.20%. Medifast's revenue for the quarter was down 34.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.87 EPS.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, September 7th. Shareholders of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 dividend on an annualized basis and a yield of 8.62%. The ex-dividend date of this dividend is Monday, September 18th.
Read our dividend analysis for MED
.

Is Medifast a good dividend stock?

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 8.49%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 54.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, MED will have a dividend payout ratio of 86.73% in the coming year. This indicates that the company may not be able to sustain their current dividend.
Read our dividend analysis for MED.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $0.71-$1.32 for the period, compared to the consensus EPS estimate of $1.43. The company issued revenue guidance of $220.00 million-$240.00 million, compared to the consensus revenue estimate of $269.57 million.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.70%), Renaissance Technologies LLC (6.25%), State Street Corp (3.51%), Dimensional Fund Advisors LP (3.10%), Pacer Advisors Inc. (2.22%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $76.56.

How much money does Medifast make?

Medifast (NYSE:MED) has a market capitalization of $833.74 million and generates $1.60 billion in revenue each year. The specialty retailer earns $143.57 million in net income (profit) each year or $12.12 on an earnings per share basis.

How many employees does Medifast have?

The company employs 874 workers across the globe.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.

This page (NYSE:MED) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -